Canaccord Genuity appointed Kyle Mikson as a director, senior equity research analyst covering the life science tools and diagnostics sector.
Mr. Mikson will focus on expanding the firm’s footprint on important emerging growth trends, such as genomics, molecular diagnostics, liquid biopsy, proteomics and spatial biology.
He joins Canaccord after several years leading equity research efforts in the life science tools and diagnostics sector. He also has prior industry experience in finance roles at Express Scripts, a pharmaceutical benefit management company.
In addition to the life science tools and diagnostics, Canaccord’s healthcare coverage includes biotechnology, medical technology, healthcare services and healthcare IT.
